Medmira (TSE:MIR) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
MedMira Inc. has announced the launch of clinical trials for its innovative Multiplo Complete Syphilis Antibody Test in Canada, aiming to offer a rapid and cost-effective solution for syphilis healthcare. The test, which is unique in providing both screening and confirmation in under 3 minutes, is expected to be a significant addition to the Canadian healthcare sector in addressing the syphilis health crisis. The trials are supported by a partnership with REACH Nexus and funded by the Canadian Institute of Health Research.
For further insights into TSE:MIR stock, check out TipRanks’ Stock Analysis page.
